Proadifen hydrochloride (SKF-525A), Cytochrome P450 inhibitor

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Cytochrome P450 3A4 also known as CYP3A4 is an enzyme that plays an important role in the metabolism of many xenobiotics and endogenous compounds. It belongs to the cytochrome P450 superfamily and is a monooxygenase with a mass of approximately 57 kDa. CYP3A4 is primarily expressed in the liver and small intestine although it can be found in other tissues at lower levels. This enzyme catalyzes the oxidation of a wide variety of structurally unrelated compounds facilitating their excretion. Proadifen is a known inhibitor of CYP3A4 often used in research to study the effects of enzyme inhibition.

Biological function summary

CYP3A4 is involved in the metabolism of approximately half of all drugs used in clinical settings making it one of the most significant enzymes in drug metabolism. It does not usually function as part of a larger complex but acts individually on various substrates. Besides xenobiotic metabolism CYP3A4 also metabolizes steroids and other endogenous molecules. Climbazole an antifungal agent is a substrate for CYP3A4 demonstrating the enzyme's broad substrate specificity within the body's complex biochemical environment.

Pathways

CYP3A4 plays a central role in the drug metabolism pathway and the synthesis and metabolism of steroids. These pathways involve other cytochrome P450 enzymes including CYP2D6 and CYP2C9 which often work alongside CYP3A4 to metabolize compounds. The pathway's coordinated activities ensure proper drug metabolism and hormone regulation. Understanding the involvement of CYP3A4 in these pathways is critical for drug development and determining drug-drug interactions.

Associated diseases and disorders

CYP3A4 is associated with conditions such as drug-induced liver injury and variable drug responses. Alterations in CYP3A4 activity can lead to either toxic accumulations or reduced efficacy of medications. Additionally certain liver diseases can alter CYP3A4 expression further complicating treatment outcomes. The enzyme's interaction with other proteins like those of the cytochrome P450 family means that any dysfunctions can impact a wide range of metabolic processes and influence disease progression.